Messaoud OUAZAA discusses the complex issue of doping in high-level sports, including its historical evolution, strategies used, detection methods, and efforts to combat the practice. The article also touches on the legal evolution of pharmacy, balancing public health and economic imperatives, the benefits and limitations of phytotherapy, the preparation of low-dose aspirin capsules in hospitals, the role of quantum dots in pharmaceutical sciences, drug stability, the development of multifunctional nanoparticles for image-assisted radiotherapy, general recommendations for drug preparation in pharmacies, and the significant impact of health system reform on the pharmaceutical industry.

Pharmainvest is committed to developing a transparency policy for its members, prioritizing the interests of pharmacists associated with the collective success of their cooperative. The company offers a range of services to optimize pharmacy operations, including training and telephone information. With a regional geographical implementation, Pharmainvest provides logistical flexibility and responsiveness, making it a key player in pharmaceutical distribution. Founded in 2001 in El Eulma by pharmacists for pharmacists, Pharmainvest supports the daily practice and development of pharmacists, ensuring pharmaceutical safety and independence.

The May 2021 issue of The Pharmacist's Bulletin, number 046, has been published, featuring articles on health data management by Yassine Leghrib, the discovery of an anti-diabetic peptide from food by Dr. Nora Khaldi's team, the 2017 finance law and drug reimbursement policies, a profile of pharmacist shareholder Abdelmadjid Fatmi, and research on new antibiotics by the National Center for Biotechnology Research.

The April 2021 issue of The Pharmacist's Bulletin, number 045, has been published, featuring topics such as public support measures for the industry by Yassine Leghrib, health-related services for the elderly in pharmacies, strengthening of the regulatory framework by the MIP, a pharmacist profile on Hayet Bourghoud and her humanitarian work, and health services including vaccination in pharmacies.

The Algerian Ministry of Health, through its General Directorate of Pharmacy and Equipment (DGPE), has taken action to halt the marketing of a product known as 'RHB'. The decision was communicated in a note dated December 13, instructing health and pharmacy directors across regions to ensure the cessation of RHB's marketing, though the reasons were not specified. The product, which was introduced to the market on November 20 at a price of 1760 DA and is not reimbursable, has been the subject of scrutiny and warnings from various medical and pharmaceutical organizations. These organizations have emphasized the importance of adhering to legal and scientific protocols for therapeutic practices and have warned against the use of RHB until further analysis is completed. The Ministry of Commerce had previously alerted citizens about the product, advising against its purchase pending analysis results. The National Council of the Order of Pharmacists has also issued a statement advising pharmacists to educate diabetic patients on the difference between dietary supplements and pharmaceutical products.